Register here:

Syngene reserves the right, at its discretion, to change, modify, add, or remove participation.

Missed learning about Targeted Protein Degradation? Please fill out the registration form to watch the full episode of our on-demand webinar on Targeted Protein Degradation: A new therapeutic modality.
 
Key discussion points:
  • How a drug can access previously inaccessible proteins and bring together genetic knock-down and knockout effects
     
  • How to control the extent of protein degradation and how difficult is it to attenuate the degree of modulation of the target protein
     
  • Why the approach of new modalities like Antibody conjugates are viable as compared to traditional medicine
     
  • How C4T’s TORPEDO™ platform (Target ORiented ProtEin Degrader Optimizer) works to accelerate drug design
     
  • C4T’s goals for the next 5 years and how the partnership with Syngene, fits in with its core strategy

© Syngene International Ltd.
Syngene International Ltd. Biocon Park, SEZ, Bommasandra Industrial Area - Phase - IV, Bangalore 560099 India

Moderator: Ashu Tandon | Chief Commercial Officer, Syngene International

Ashu has 20 years experience in the global biopharmaceuticals industry which includes Sales and Account Management leadership across consulting, and outsourcing services in Research & Development. He has a successful track record of building multi-million dollar deals across multiple industry verticals and geographies.

As a member of Syngene's Executive Committee, he plays an important role in driving strategy related to Commercial activities. Prior to joining Syngene, Ashu was with IQVIA (formerly QuintilesIMS), Infosys and Accenture.

Panelist 1: Chris Nasveschuk, Ph.D. | Vice President – Chemistry, C4 Therapeutics

Chris joined C4 Therapeutics in February 2016 and currently serves as Vice President, Chemistry, C4. Prior to C4, he was with the Center for Development of Therapeutics (CDoT) team at Broad Institute, Colorado University, where he was leading a group of medicinal chemists in projects spanning cancer, metabolism and autophagy disease areas. Chris also worked for Constellation Pharmaceuticals where he was part of the team that helped discover and develop the BET inhibitor, CPI-0610, currently in Phase I clinical trials. He also contributed to expanding the intellectual property footprint around this molecule. Chris is most proud of his work on PRC2/EZH2 as a co-inventor of CPI-1205, also in Phase I clinical trials
 
Chris holds a Ph.D. in Organic Chemistry from Colorado State University and a BS in Chemistry from Middlebury College.

Panelist 2: Kenneth Barr, Ph.D. | Sr. Vice President – Discovery Services, Syngene International

Kenneth has over two decades of experience in the areas of drug discovery for both small and large molecules and associated with organisations like Merck, Amplyx Pharmaceuticals Inc. and Sunesis.
 
Prior to joining Syngene, Kenneth was the Head of R&D Strategic Global Operations, FORMA Therapeutics. At FORMA, he was responsible for driving research effectiveness through optimisation of internal and external R&D research efforts and providing alliance management for key CRO relationships.
 
Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology. He pursued his Postdoctoral study in Natural product synthesis from the University of Texas.